Oncology Central

Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review

0

This systematic review aims at assessment of the available evidence for systemic therapy options for patients with advanced gastrointestinal stromal tumors beyond first-line imatinib. Eligible trials were identified using databases search. In total, 26 studies were eligible and included in the final analysis. Among second-line studies, median progression-free survival ranged from 1.9 to 10 months while median overall survival ranged from 15 to 62 months.

To view restricted content, please:
Share:

Leave A Comment